JPH07100662B2 - 治療用組成物 - Google Patents

治療用組成物

Info

Publication number: JPH07100662B2
Authority: JP; Japan
Prior art keywords: necrosis factor; tumor necrosis; alpha; factor alpha; cgd
Prior art date: 1986-06-16
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

JP62150069A

Other languages

English (en)

Japanese (ja)

Other versions

JPS6354327A (ja

Inventor

ミカエル・アンジェロ・パラディノ

アーサー・ジェイ・アマン

Original Assignee

ジエネンテク，インコ−ポレイテツド

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-06-16

Filing date

1987-06-16

Publication date

1995-11-01

1987-06-16 Application filed by ジエネンテク，インコ−ポレイテツド filed Critical ジエネンテク，インコ−ポレイテツド

1988-03-08 Publication of JPS6354327A publication Critical patent/JPS6354327A/ja

1995-11-01 Publication of JPH07100662B2 publication Critical patent/JPH07100662B2/ja

2010-11-01 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

239000000203 mixture Substances 0.000 title description 17
230000001225 therapeutic effect Effects 0.000 title description 3
108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 69
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 69
239000003814 drug Substances 0.000 claims description 17
229940124597 therapeutic agent Drugs 0.000 claims description 12
239000000546 pharmaceutical excipient Substances 0.000 claims description 7
230000001684 chronic effect Effects 0.000 claims description 6
238000002360 preparation method Methods 0.000 claims description 5
230000000699 topical effect Effects 0.000 claims description 5
239000003242 anti bacterial agent Substances 0.000 claims description 3
239000006172 buffering agent Substances 0.000 claims 1
239000002552 dosage form Substances 0.000 claims 1
229940102223 injectable solution Drugs 0.000 claims 1
210000003622 mature neutrocyte Anatomy 0.000 description 57
208000016532 chronic granulomatous disease Diseases 0.000 description 35
101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 21
102000057041 human TNF Human genes 0.000 description 21
210000001539 phagocyte Anatomy 0.000 description 18
230000000694 effects Effects 0.000 description 14
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 14
210000004027 cell Anatomy 0.000 description 12
238000009472 formulation Methods 0.000 description 11
238000004519 manufacturing process Methods 0.000 description 11
238000011282 treatment Methods 0.000 description 11
239000011324 bead Substances 0.000 description 10
208000015181 infectious disease Diseases 0.000 description 10
230000000638 stimulation Effects 0.000 description 10
244000052769 pathogen Species 0.000 description 9
108010074328 Interferon-gamma Proteins 0.000 description 8
239000012049 topical pharmaceutical composition Substances 0.000 description 8
108010086652 phytohemagglutinin-P Proteins 0.000 description 7
230000004044 response Effects 0.000 description 7
206010057249 Phagocytosis Diseases 0.000 description 6
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
230000002950 deficient Effects 0.000 description 6
239000001301 oxygen Substances 0.000 description 6
229910052760 oxygen Inorganic materials 0.000 description 6
230000008782 phagocytosis Effects 0.000 description 6
239000000243 solution Substances 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
102100037850 Interferon gamma Human genes 0.000 description 5
102000004083 Lymphotoxin-alpha Human genes 0.000 description 5
108090000542 Lymphotoxin-alpha Proteins 0.000 description 5
238000001994 activation Methods 0.000 description 5
230000001580 bacterial effect Effects 0.000 description 5
244000052616 bacterial pathogen Species 0.000 description 5
239000000969 carrier Substances 0.000 description 5
229940079593 drug Drugs 0.000 description 5
238000000034 method Methods 0.000 description 5
210000005087 mononuclear cell Anatomy 0.000 description 5
210000005259 peripheral blood Anatomy 0.000 description 5
239000011886 peripheral blood Substances 0.000 description 5
102000004169 proteins and genes Human genes 0.000 description 5
108090000623 proteins and genes Proteins 0.000 description 5
208000035473 Communicable disease Diseases 0.000 description 4
206010028980 Neoplasm Diseases 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
230000004913 activation Effects 0.000 description 4
230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
239000008280 blood Substances 0.000 description 4
239000000872 buffer Substances 0.000 description 4
239000006071 cream Substances 0.000 description 4
230000003013 cytotoxicity Effects 0.000 description 4
231100000135 cytotoxicity Toxicity 0.000 description 4
239000003623 enhancer Substances 0.000 description 4
239000012091 fetal bovine serum Substances 0.000 description 4
238000001943 fluorescence-activated cell sorting Methods 0.000 description 4
244000053095 fungal pathogen Species 0.000 description 4
239000000499 gel Substances 0.000 description 4
230000002147 killing effect Effects 0.000 description 4
239000004816 latex Substances 0.000 description 4
229920000126 latex Polymers 0.000 description 4
230000001404 mediated effect Effects 0.000 description 4
244000005700 microbiome Species 0.000 description 4
239000007758 minimum essential medium Substances 0.000 description 4
210000000440 neutrophil Anatomy 0.000 description 4
230000000242 pagocytic effect Effects 0.000 description 4
150000002978 peroxides Chemical class 0.000 description 4
239000003755 preservative agent Substances 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 3
241000222122 Candida albicans Species 0.000 description 3
102000008070 Interferon-gamma Human genes 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
229920000392 Zymosan Polymers 0.000 description 3
230000002924 anti-infective effect Effects 0.000 description 3
229960005475 antiinfective agent Drugs 0.000 description 3
239000004599 antimicrobial Substances 0.000 description 3
239000011575 calcium Substances 0.000 description 3
229940095731 candida albicans Drugs 0.000 description 3
230000007547 defect Effects 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
210000003979 eosinophil Anatomy 0.000 description 3
DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 3
239000004615 ingredient Substances 0.000 description 3
229960003130 interferon gamma Drugs 0.000 description 3
239000003226 mitogen Substances 0.000 description 3
150000003839 salts Chemical class 0.000 description 3
210000003491 skin Anatomy 0.000 description 3
239000003381 stabilizer Substances 0.000 description 3
239000000126 substance Substances 0.000 description 3
239000003981 vehicle Substances 0.000 description 3
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
FTEDXVNDVHYDQW-UHFFFAOYSA-N BAPTA Chemical compound OC(=O)CN(CC(O)=O)C1=CC=CC=C1OCCOC1=CC=CC=C1N(CC(O)=O)CC(O)=O FTEDXVNDVHYDQW-UHFFFAOYSA-N 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
208000035143 Bacterial infection Diseases 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
241000588724 Escherichia coli Species 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 2
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
102000007327 Protamines Human genes 0.000 description 2
108010007568 Protamines Proteins 0.000 description 2
206010038687 Respiratory distress Diseases 0.000 description 2
RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
230000000844 anti-bacterial effect Effects 0.000 description 2
229940088710 antibiotic agent Drugs 0.000 description 2
208000022362 bacterial infectious disease Diseases 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
210000002889 endothelial cell Anatomy 0.000 description 2
210000003743 erythrocyte Anatomy 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
210000002950 fibroblast Anatomy 0.000 description 2
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical class O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
102000043557 human IFNG Human genes 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
230000003834 intracellular effect Effects 0.000 description 2
238000010255 intramuscular injection Methods 0.000 description 2
239000007927 intramuscular injection Substances 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
210000002540 macrophage Anatomy 0.000 description 2
239000000463 material Substances 0.000 description 2
238000005259 measurement Methods 0.000 description 2
239000002609 medium Substances 0.000 description 2
239000003921 oil Substances 0.000 description 2
239000002674 ointment Substances 0.000 description 2
230000036284 oxygen consumption Effects 0.000 description 2
-1 oxygen radicals Chemical class 0.000 description 2
230000035515 penetration Effects 0.000 description 2
235000019271 petrolatum Nutrition 0.000 description 2
230000015323 positive regulation of phagocytosis Effects 0.000 description 2
230000002335 preservative effect Effects 0.000 description 2
229940048914 protamine Drugs 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
230000029058 respiratory gaseous exchange Effects 0.000 description 2
238000000926 separation method Methods 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
239000004094 surface-active agent Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
238000012360 testing method Methods 0.000 description 2
230000006433 tumor necrosis factor production Effects 0.000 description 2
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
241001225321 Aspergillus fumigatus Species 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
206010007882 Cellulitis Diseases 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
108010092160 Dactinomycin Proteins 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
238000012286 ELISA Assay Methods 0.000 description 1
239000006145 Eagle's minimal essential medium Substances 0.000 description 1
206010017533 Fungal infection Diseases 0.000 description 1
241000233866 Fungi Species 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
102000006395 Globulins Human genes 0.000 description 1
108010044091 Globulins Proteins 0.000 description 1
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
102000000588 Interleukin-2 Human genes 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
241000588915 Klebsiella aerogenes Species 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
239000004166 Lanolin Substances 0.000 description 1
102000008072 Lymphokines Human genes 0.000 description 1
108010074338 Lymphokines Proteins 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
208000031888 Mycoses Diseases 0.000 description 1
206010028851 Necrosis Diseases 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
201000005702 Pertussis Diseases 0.000 description 1
239000004264 Petrolatum Substances 0.000 description 1
241001483078 Phyto Species 0.000 description 1
206010035664 Pneumonia Diseases 0.000 description 1
229920002701 Polyoxyl 40 Stearate Polymers 0.000 description 1
241000191967 Staphylococcus aureus Species 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
208000033809 Suppuration Diseases 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
239000002253 acid Substances 0.000 description 1
RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
229940024546 aluminum hydroxide gel Drugs 0.000 description 1
SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000001775 anti-pathogenic effect Effects 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
229910052786 argon Inorganic materials 0.000 description 1
238000000149 argon plasma sintering Methods 0.000 description 1
229940091771 aspergillus fumigatus Drugs 0.000 description 1
238000003556 assay Methods 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
229910001424 calcium ion Inorganic materials 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
239000013553 cell monolayer Substances 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
230000003833 cell viability Effects 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
229960000541 cetyl alcohol Drugs 0.000 description 1
230000009920 chelation Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000003759 clinical diagnosis Methods 0.000 description 1
239000005515 coenzyme Substances 0.000 description 1
238000011109 contamination Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
230000016396 cytokine production Effects 0.000 description 1
230000001461 cytolytic effect Effects 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
229960000640 dactinomycin Drugs 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
238000006073 displacement reaction Methods 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
238000009826 distribution Methods 0.000 description 1
239000003792 electrolyte Substances 0.000 description 1
239000003974 emollient agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
239000002158 endotoxin Substances 0.000 description 1
108010072542 endotoxin binding proteins Proteins 0.000 description 1
229940092559 enterobacter aerogenes Drugs 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
230000004907 flux Effects 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
230000009395 genetic defect Effects 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
229940075529 glyceryl stearate Drugs 0.000 description 1
230000009215 host defense mechanism Effects 0.000 description 1
239000003906 humectant Substances 0.000 description 1
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
230000036737 immune function Effects 0.000 description 1
208000026278 immune system disease Diseases 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
229940039717 lanolin Drugs 0.000 description 1
235000019388 lanolin Nutrition 0.000 description 1
230000003902 lesion Effects 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
229920006008 lipopolysaccharide Polymers 0.000 description 1
239000002502 liposome Substances 0.000 description 1
210000001165 lymph node Anatomy 0.000 description 1
201000003265 lymphadenitis Diseases 0.000 description 1
230000002101 lytic effect Effects 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
210000004379 membrane Anatomy 0.000 description 1
239000012528 membrane Substances 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
239000011859 microparticle Substances 0.000 description 1
239000004005 microsphere Substances 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
230000017074 necrotic cell death Effects 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
244000045947 parasite Species 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
229940066842 petrolatum Drugs 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920000098 polyolefin Polymers 0.000 description 1
239000001103 potassium chloride Substances 0.000 description 1
235000011164 potassium chloride Nutrition 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000011533 pre-incubation Methods 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
238000011084 recovery Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
230000019254 respiratory burst Effects 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
210000002345 respiratory system Anatomy 0.000 description 1
238000004062 sedimentation Methods 0.000 description 1
206010040872 skin infection Diseases 0.000 description 1
239000012064 sodium phosphate buffer Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
241000894007 species Species 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
230000004797 therapeutic response Effects 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
210000003606 umbilical vein Anatomy 0.000 description 1
239000008215 water for injection Substances 0.000 description 1
239000003871 white petrolatum Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Immunology (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

JP62150069A 1986-06-16 1987-06-16 治療用組成物 Expired - Lifetime JPH07100662B2 (ja)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date
US87473686A	1986-06-16	1986-06-16
US874736		1986-06-16
US5393887A	1987-05-22	1987-05-22
US53938		1987-05-22

Publications (2)

Publication Number	Publication Date
JPS6354327A JPS6354327A (ja)	1988-03-08
JPH07100662B2 true JPH07100662B2 (ja)	1995-11-01

Family

ID=26732412

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP62150069A Expired - Lifetime JPH07100662B2 (ja)	1986-06-16	1987-06-16	治療用組成物

Country Status (8)

Country	Link
EP (1)	EP0250192A3 (de)
JP (1)	JPH07100662B2 (de)
AU (1)	AU598817B2 (de)
DK (1)	DK302887A (de)
IL (1)	IL82862A0 (de)
NZ (1)	NZ220686A (de)
PH (1)	PH26613A (de)
PT (1)	PT85076B (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ219027A (en) *	1986-01-24	1989-09-27	Genentech Inc	Antiviral composition containing interferon tumour necrosis factor and/or lymphotoxin
DE3613166A1 (de) *	1986-04-18	1987-10-29	Basf Ag	Verwendung von tnf zur herstellung von arzneimitteln
US5322699A (en) *	1991-02-04	1994-06-21	The Rockefeller University	Leukocyte-derived CR3 modulator, integrin modulating factor-1 (IMF-1)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3472793D1 (en) *	1983-12-26	1988-08-25	Asahi Chemical Ind	A novel physiologically active polypeptide
DE3423234A1 (de) *	1984-06-23	1986-02-06	Boehringer Ingelheim International GmbH, 6507 Ingelheim	Synergistische mischungen von interferonen und tumor-nekrose-faktor
GR851626B (de) *	1984-07-05	1985-11-26	Genentech Inc
US4879111A (en) *	1986-04-17	1989-11-07	Cetus Corporation	Treatment of infections with lymphokines

1987
- 1987-06-12 PT PT85076A patent/PT85076B/pt unknown
- 1987-06-14 IL IL82862A patent/IL82862A0/xx unknown
- 1987-06-15 DK DK302887A patent/DK302887A/da not_active Application Discontinuation
- 1987-06-15 AU AU74223/87A patent/AU598817B2/en not_active Expired
- 1987-06-15 EP EP87305286A patent/EP0250192A3/de not_active Withdrawn
- 1987-06-15 PH PH35409A patent/PH26613A/en unknown
- 1987-06-15 NZ NZ220686A patent/NZ220686A/xx unknown
- 1987-06-16 JP JP62150069A patent/JPH07100662B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
DK302887D0 (da)	1987-06-15
EP0250192A3 (de)	1988-02-10
DK302887A (da)	1987-12-17
PT85076B (pt)	1990-07-31
PT85076A (en)	1987-07-01
PH26613A (en)	1992-08-19
IL82862A0 (en)	1987-12-20
JPS6354327A (ja)	1988-03-08
AU7422387A (en)	1987-12-17
NZ220686A (en)	1990-02-26
EP0250192A2 (de)	1987-12-23
AU598817B2 (en)	1990-07-05

Legal Events

Date	Code	Title	Description
2004-11-02	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2005-11-08	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2006-11-07	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2007-06-16	EXPY	Cancellation because of completion of term
2007-09-12	FPAY	Renewal fee payment (event date is renewal date of database)	Free format text: PAYMENT UNTIL: 20071101 Year of fee payment: 12

Publication	Publication Date	Title
Godal et al.	1971	Characterization of the cellular immune defect in lepromatous leprosy: a specific lack of circulating Mycobacterium leprae-reactive lymphocytes
Thueson et al.	1979	Histamine-releasing activity (HRA) I. Production by mitogen-or antigen-stimulated human mononuclear cells
BORDEN et al.	1982	Leukocyte-derived interferon (alpha) in human breast carcinoma: the American Cancer Society phase II trial
JP3810741B2 (ja)	2006-08-16	修飾ｃ反応性タンパク質を使用する癌細胞検出用組成物
GB1558943A (en)	1980-01-09	Fractonation process
Weiss et al.	1997	Modulatory potential of iron chelation therapy on nitric oxide formation in cerebral malaria
HILL et al.	1976	Recurrent staphylococcal abscesses associated with defective neutrophil chemotaxis and allergic rhinitis
Webster et al.	1974	The ampicillin rash. Lymphocyte transformation by ampicillin polymer
COLBY et al.	1977	Cellular hypersensitivity in attacks of multiple sclerosis: 1. A comparative study of migration inhibitory factor production and lymphoblastic transformation in response to myelin basic protein in multiple sclerosis
Kaplan et al.	1986	Effect of recombinant interferon-gamma on hydrogen peroxide-releasing capacity of monocyte-derived macrophages from patients with lepromatous leprosy.
KR20020053064A (ko)	2002-07-04	질병 치료를 위한 저용량의 ｉｆｎ-감마
Jilma et al.	1998	Glucocorticoids dose-dependently increase plasma levels of granulocyte colony stimulating factor in man
JPH07100662B2 (ja)	1995-11-01	治療用組成物
JP2784401B2 (ja)	1998-08-06	慢性骨髄性白血病の治療方法
CA1316818C (en)	1993-04-27	Therapeutic compositions containing tumor necrosis factor-alpha
CA2300792A1 (en)	2000-09-19	An agent for increasing chemokine production
Ishii et al.	1990	Detection of tumour necrosis factor/cachectin in pleural effusion of patients with lung cancer
Górski	1974	Superiority of corpuscular BCG to soluble PPD antigen in the leucocyte migration assay
Bygbjerg et al.	1986	Effect of pyrimethamine and sulphadoxine on human lymphocyte proliferation
Einhorn et al.	1984	Functions of human neutrophilic granulocytes after in vivo exposure to interferon alpha
RU2118159C1 (ru)	1998-08-27	Способ терапии острой пневмонии
EP1171160B1 (de)	2005-06-01	Methode und mittel zur behandlung eines post-poliosyndroms
BYGBJERG	1981	AUGMENTATION OF HUMAN LYMPHOCYTE PROLIFERATIVE RESPONSES IN VITROBY PYRIMETHAMINE
Mattsson et al.	1983	Bestatin treatment for the correction of granulocyte dysfunction in patients with recurrent furunculosis
JP2003137784A (ja)	2003-05-14	インターフェロンγ産生促進剤